On October 23, 2024 ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, reported that it will present new preclinical data about the potential of IMPT-601, a Claudin18.2/transforming growth factor beta (TGF-β) bispecific CAR T-cell therapy for the treatment of gastric cancer (Press release, ImmPACT-Bio, OCT 23, 2024, View Source;bispecific-car-t-cell-therapy-impt-601-for-gastric-cancer-at-the-sitc-39th-annual-meeting-302282396.html [SID1234647353]). These data were selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting, to be held November 8-10, 2024 in Houston, TX.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IMPT-601 is designed to overcome the suppressive tumor microenvironment by enhancing CAR T-cell infiltration, overcoming T-cell exhaustion, and reducing regulatory T-cell numbers through dual targeting of Claudin 18.2 and TGF-β.
Details for the presentation are as follows:
Title: Therapeutic Potential of IMPT-601, a Claudin18.2/TGF-β Bispecific CAR, Against Gastric Cancer
Abstract Number: 298
Presenter: Melanie L. Munguia, ImmPACT Bio
Session: Oral Abstract Session 2
Date and Time: Saturday, November 9, 2024, 3:25 – 4:45 PM CDT
Location: Exhibit Halls A B George R. Brown Convention Center
Abstracts and additional details can be found at the SITC (Free SITC Whitepaper) 39th Annual Meeting website.